Clinical Services

FDA Approves TAVR for Low-Risk Patients

Earlier this month, the US Food and Drug Administration approved the use of transcatheter heart valve replacement (TAVR) for the treatment of severe, symptomatic aortic stenosis in patients who are determined to be at low risk of complications from open-heart surgery. Previously, the procedure was reserved for high-risk and intermediate-risk patients.

The newly approved indication offers an alternative approach for treatment to a large group of patients for whom open heart surgery was the only option when medical therapy was not effective.

Since its initial approval by the FDA in 2011, the heart valve team at Englewood has performed more than 600 TAVR procedures, making us one of the leading centers in New Jersey. The TAVR team consists of both interventional cardiologists and cardiothoracic surgeons who work together to perform the procedure in the hybrid operating room.

TAVR uses balloon-expandable and self-expanding valves, delivered via a catheter into the heart, to provide the best possible outcomes for our patients. Watch this animation to learn more about how the procedure works.

The Englewood Health TAVR team

To refer a patient to the heart valve team, contact Denise Goldstein, APN, valve coordinator, denise.goldstein@ehmchealth.org or 201-894-3636, or any of the team members: Drs. Adam Arnofsky, Michael Benz, Joseph De Gregorio, Richard Goldweit, Ramin Hastings, Lance Kovar, Molly Schultheis, Aron Schwarcz, and Hartaj Virk.